A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

Qihua Tan, Anaïs Marie Julie Møller, Chuan Qiu, Jonna Skov Madsen, Hui Shen, Troels Bechmann, Jean-Marie Delaissé, Bjarne Winther Kristensen, Hong-Wen Deng, David Karasik, Kent Søe*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

32 Downloads (Pure)

Abstract

Background: Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity to zoledronic acid >200-fold, determined by the half-maximal inhibitory concentration (IC50), with cigarette smoking as one of the reported contributors to this variation. To reveal the molecular basis of the smoking-mediated variation on treatment sensitivity, we performed a DNA methylome profiling on whole blood cells from 34 healthy female blood donors. Multiple regression models were fitted to associate DNA methylation with ex vivo determined IC50 values, smoking, and their interaction adjusting for age and cell compositions. Results: We identified 59 CpGs displaying genome-wide significance (p
Original languageEnglish
Article number42
JournalClinical Epigenetics
Volume15
Issue number1
Number of pages14
ISSN1868-7083
DOIs
Publication statusPublished - 13. Mar 2023

Fingerprint

Dive into the research topics of 'A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome'. Together they form a unique fingerprint.

Cite this